<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134571">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02017379</url>
  </required_header>
  <id_info>
    <org_study_id>E13018</org_study_id>
    <nct_id>NCT02017379</nct_id>
  </id_info>
  <brief_title>Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study comparing the effect of erythromycin or metoclopramide, 2 prokinetic drugs
      (Drugs which are known to speed up the emptying of the stomach or in other words to move the
      blood out of the stomach faster) given before endoscopy to patients with upper
      Gastrointestinal bleeding compared to patients who will not receive either of these
      medications before their endoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy of pre-endoscopic interventions namely erythromycin, metoclopromide
      vs control in improving the outcomes of endoscopy in ICU patients admitted upper GI
      bleeding.

      Specific aims:

        1. Wither erythromycin, metoclopromide vs control can enable visualization of the entire
           gastric mucosa .

        2. Wither erythromycin, metoclopromide vs control  can improve the quality of stomach and
           duodenum visualization: using the scoring system by Fossard et al
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>1. Wither erythromycin, metoclopromide vs control can enable visualization of the entire gastric mucosa .</measure>
    <time_frame>45 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Wither erythromycin, metoclopromide vs control  can improve the quality of stomach and duodenum visualization: using the scoring system by Fossard et al</measure>
    <time_frame>45 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to identify the source of bleeding</measure>
    <time_frame>45 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for second-look endoscopy</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of blood units transfused</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Upper Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous erythromycin infusion (dose: 250 mg)  30 min-60 min before procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no medications will be given prior to endoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <arm_group_label>Erythromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopromide</intervention_name>
    <arm_group_label>Metoclopromide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18-80)

          -  who are admitted to the ICU for hematemesis, or coffee ground emesis

        Exclusion Criteria:

          1. Patients younger than 18 yrs old or older than 80 yrs

          2. Patients who refuse to consent to be in our study

          3. Pregnant patients

          4. Prior use of prokinetics in the last 48 hours

          5. History of cardiac arrhythmia

          6. Allergy to erythromycin or metoclopromide

          7. Patients with QT prolongation (query 7)

             -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myrna Arvizo, BMS, CIP, CHRC</last_name>
      <phone>915) 215-4162</phone>
      <email>myrna.arvizo@ttuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamed Othman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Zuckerman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Eloliby, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>upper gastrointestinal bleeding</keyword>
  <keyword>melena</keyword>
  <keyword>hematemesis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
